Press Room

Press Clipping / Dec 05, 2017

Economic and environmental benefits from energy-efficient compressed-air system

Engineers Journal, December 5, 2017

HSEE Health Safety Environment | Hovione

Energy-efficient compressors and visualisation software have given Cork-based pharmaceutical firm Hovione more control over operating costs and energy use, writes Kenneth Lloyd.

Hovione, a Cork-based pharmaceutical firm, has realised multiple benefits from leasing a high-end compressed air system under a lease agreement. The Portuguese pharmaceutical firm acquired its Cork site in 2009. It was a state-of-the-art facility although, inevitably, the company inherited some older equipment. In 2015, it was apparent that the compressed air system needed to be replaced due to inefficiencies and reliability concerns.

However, the company had a preference for leasing, as opposed to buying, the equipment in this instance. It appointed compressed air solutions experts, O’Neill Industrial, to provide a new compressed air system under a lease agreement.

The benefits of leasing the equipment in contrast to buying were multiple for Hovione: it has...

 

Read the article

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026